Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP3082 + Carboplatin + Pemetrexed Disodium |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP3082 | ASP 3082|ASP-3082 | KRAS G12D Inhibitor 25 | ASP3082 degrades KRAS G12D, potentially leading to decreased Erk phosphorylation and inhibition of cell growth and tumor regression (European Journal of Cancer 174 (2022): S30). | |
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| Pemetrexed Disodium | Alimta | LY231514|Ciambra|pemetrexed | Chemotherapy - Antimetabolite 14 | Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05382559 | Phase I | ASP3082 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin ASP3082 ASP3082 + Pembrolizumab ASP3082 + Cisplatin + Pemetrexed Disodium ASP3082 + Gemcitabine + Nab-paclitaxel ASP3082 + Carboplatin + Pemetrexed Disodium ASP3082 + Cisplatin + Pembrolizumab + Pemetrexed Disodium ASP3082 + Cetuximab ASP3082 + Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Study of ASP3082 in Adults With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | 3 |